Simvastatin and lovastatin, but not pravastatin, interact with MDR1

Journal of Pharmacy and Pharmacology

Volumn 54, Issue 3, 2002, Pages 419-423

  Sakaeda, T ^a   Takara, K ^b   Kakumoto, M ^a   Ohmoto, N ^a   Nakamura, T ^a   Iwaki, K ^a   Tanigawara, Y ^c   Okumura, K ^a  

^a KOBE UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DIGOXIN; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LINE; CELL TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; DNA TRANSFECTION; DOSE RESPONSE; DRUG TRANSPORT; EPITHELIUM CELL; HYDROPHOBICITY; KIDNEY EPITHELIUM; MOLECULAR INTERACTION; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SWINE;

ANIMALS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DIGOXIN; DRUG INTERACTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; P-GLYCOPROTEIN; PRAVASTATIN; SIMVASTATIN; SWINE;

EID: 0036121513     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357021778493     Document Type: Article

References (26)

1. HMG-CoA reductase inhibitors and P-glycoprotein modulation
2. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin
3. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
4. Expression of the mdr1 P-glycoprotein gene: A mechanism of escape from glucocorticoid-induced apoptosis
5. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
6. Interrelationship between substrates and inhibitors of human CYP3A4 and P-glycoprotein
7. Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin
8. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein
9. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
10. Clinical pharmacokinetics and practical applications of simvastatin
11. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
12. Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney
13. Clinical pharmacokinetics of pravastatin
14. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin
15. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
16. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs
17. Nicardipine and itraconazole inhibited cellular transport of digoxin
18. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1)
19. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
20. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone
21. How does P-glycoprotein recognize its substrates?
22. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
23. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
24. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies
25. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein
26. Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter